Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNα2b

Clinical Cancer Research

Volumn 13, Issue 5, 2007, Pages 1523-1531

  Wang, Wenjun ^a   Edington, Howard D ^b   Rao, Uma N M ^c   Jukic, Drazen M ^c,d   Land, Stephanie R ^e   Ferrone, Soldano ^f   Kirkwood, John M ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; STAT1 PROTEIN; STAT3 PROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; LYMPHADENECTOMY; LYMPHOCYTE; MALE; MELANOMA; MODULATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR BIOPSY; TUMOR CELL; TUMOR GROWTH;

ADULT; AGED; ATP-BINDING CASSETTE TRANSPORTERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON ALFA-2B; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOADJUVANT THERAPY; SKIN NEOPLASMS; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33947423447     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1387     Document Type: Article

References (53)

1. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:1670-7.
2. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon α-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-80.
3. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
4. Gamero AM, Young HA, Wiltrout RH. Inactivation of Stat3 in tumor cells: releasing a brake on immune responses against cancer? Cancer Cell 2004;5:111-2.
5. O'Shea JJ, Pesu M, Borie DC, Changelian PS. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov 2004;3:555-64.
6. Lesinski GB, Anghelina M, Zimmerer J, et al. The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse. J Clin Invest 2003;112:170-80.
7. Kirkwood JM, Farkas DL, Chakraborty A, et al. Systemic interferon-α (IFN-α) treatment leads to Stat3 inactivation in melanoma precursor lesions. Mol Med 1999;5:11-20.
8. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004;10:48-54.
9. Lesinski GB, Valentino D, Hade EM, et al. Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-α adjuvant therapy. Cancer Immunol Immunother 2005;54:815-25.
10. Kortylewski M, Jove R, Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev 2005;24:315-27.
11. Xie TX, Huang FJ, Aldape KD, et al. Activation of Stat3 in human melanoma promotes brain metastasis. Cancer Res 2006;66:3188-96.
12. Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev 2004;4:97-105.
13. Bromberg J, Darnell JE, Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000;19:2468-73.
14. Bromberg JF. Activation of STAT proteins and growth control. BioEssays 2001;23:161-9.
15. Wormald S, Zhang JG, Krebs DL, et al. The comparative roles of suppressor of cytokine signaling-1 and -3 in the inhibition and desensitization of cytokine signaling. J Biol Chem 2006;281:11135-43.
16. Moschos SJ, Edington HE, Rao UN, et al. High dose interferon α2b (HDI): toxicity, response, and predictive markers in a neoadjuvant trial for regional lymph node metastatic melanoma. 2005 ASCO Annual Meeting Proceedings; 2005.
17. Wang W, Edington HE, Rao UN, et al. Effects of neoadjuvant high-dose interferon (IFNα2b) upon STAT signaling, IFNαRβ, MHC and Tap expression in lymph node metastatic melanoma (UPCI 008). 2005 Proceedings of the AACR Online; 2005: http://aacrmeetingabstracts.org.
18. Moschos SJ, Edington HD, Land SR, et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon α-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006;24:3164-71.
19. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709-18.
20. Mailliard RB, Wankowicz-Kalinska A, Cai Q, et al. α-Type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 2004;64:5934-7.
21. Okada H, Tsugawa T, Sato H, et al. Delivery of interferon-α transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines. Cancer Res 2004;64:5830-8.
22. + T cell responses against human tumor antigens. J Immunol 2004;172:5363-70.
23. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 1986;137:2299-306.
24. Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F. Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 2003;171:1918-26.
25. Temponi M, Kekish U, Hamby CV, Nielsen H, Marboe CC, Ferrone S. Characterization of anti-HLA class II monoclonal antibody LGII-612.14 reacting with formalin fixed tissues. J Immunol Methods 1993;161:239-56.
26. Wang X, Campoli M, Cho HS, et al. A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. J Immunol Methods 2005;299:139-51.
27. Efron B, Tibshirani R. An introduction to the Boostrap. New York: Chapman & Hall: 1993
28. Agrawal S, Reemtsma K, Bagiella E, Oluwole SF, Braunstein NS. Role of TAP-1 and/or TAP-2 antigen presentation defects in tumorigenicity of mouse melanoma. Cell Immunol 2004;228:130-7.
29. Seliger B, Ritz U, Abele R, et al. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 2001;61:8647-50.
30. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM. Interferon-α in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002;13:119-34.
31. Belardelli F, Gresser I. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol Today 1996;17:369-72.
32. Badgwell B, Lesinski GB, Magro C, Abood G, Skaf A, Carson W III. The antitumor effects of interferon-α are maintained in mice challenged with a STAT1-deficient murine melanoma cell line. J Surg Res 2004;116:129-36.
33. Burdelya L, Kujawski M, Niu G, et al. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol 2005;174:3925-31.
34. Yang J, Chatterjee-Kishore M, Staugaitis SM, et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 2005;65:939-47.
35. Cresswell AC, Sisley K, Laws D, Parsons MA, Rennie IG, Murray AK. Reduced expression of TAP-1 and TAP-2 in posterior uveal melanoma is associated with progression to metastatic disease. Melanoma Res 2001;11:275-81.
36. Whiteside TL, Stanson J, Shurin MR, Ferrone S. Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. J Immunol 2004;173:1526-34.
37. Abele R, Tampe R. The ABCs of immunology: structure and function of TAP, the transporter associated with antigen processing. Physiology (Bethesda) 2004;19:216-24.
38. Zhang L, Pagano JS. Interferon regulatory factor 7 mediates activation of Tap-2 by Epstein-Barr virus latent membrane protein 1. J Virol 2001;75:341-50.
39. Honda K, Yanai H, Negishi H, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005;434:772-7.
40. Remoli ME, Giacomini E, Lutfalla G, et al. Selective expression of type IIFN genes in human dendritic cells infected with Mycobacterium tuberculosis. J Immunol 2002;169:366-74.
41. Prakash A, Smith E, Lee CK, Levy DE. Tissue-specific positive feedback requirements for production of type I interferon following virus infection. J Biol Chem 2005;280:18651-7.
42. Ning S, Huye LE, Pagano JS. Regulation of the transcriptional activity of the IRF7 promoter by a pathway independent of interferon signaling. J Biol Chem 2005;280:12262-70.
43. Abuzahra F, Heise R, Joussen S, et al. Adjuvant interferon α treatment for patients with malignant melanoma stimulates transporter proteins associated with antigen processing and proteasome activator 28. Lancet Oncol 2004;5:250.
44. Rouyez MC, Lestingi M, Charon M, Fichelson S, Buzyn A, Dusanter-Fourt I. IFN regulatory factor-2 cooperates with STAT1 to regulate transporter associated with antigen processing-1 promoter activity. J Immunol 2005;174:3948-58.
45. Zhou Y, Wang S, Gobi A, Oberg K. The interferon-α regulation of interferon regulatory factor 1 (IRF-1) and IRF-2 has therapeutic implications in carcinoid tumors. Ann Oncol 2000;11:707-14.
46. Carson WE. Interferon-α-induced activation of signal transducer and activator of transcription proteins in malignant melanoma. Clin Cancer Res 1998;4:2219-28.
47. Dovhey SE, Ghosh NS, Wright KL. Loss of interferon-γ inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line. Cancer Res 2000;60:5789-96.
48. Spies T, Bresnahan M, Bahram S, et al. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature 1990;348:744-7.
49. Trowsdale J, Hanson I, Mockridge I, Beck S, Townsend A, Kelly A. Sequences encoded in the class II region of the MHC related to the "ABC" superfamily of transporters. Nature 1990;348:741-4.
50. Spies T, DeMars R. Restored expression of major histocompatibility class I molecules by gene transfer of a putative peptide transporter. Nature 1991;351:323-4.
51. Powis SJ, Townsend AR, Deverson EV, Bastin J, Butcher GW, Howard JC. Restoration of antigen presentation to the mutant cell line RMA-S by an MHC-linked transporter. Nature 1991;354:528-31.
52. Attaya M, Jameson S, Martinez CK, et al. Ham-2 corrects the class I antigen-processing defect in RMA-S cells. Nature 1992;355:647-9.
53. Yang Y, Fruh K, Chambers J, et al. Major histocompatibility complex (MHC)-encoded HAM2 is necessary for antigenic peptide loading onto class I MHC molecules. J Biol Chem 1992;267:11669-72.